Enjoy complimentary customisation on priority with our Enterprise License!
The Global Alzheimers Disease Therapeutics Market size is estimated to grow by USD 5.41 billion at a CAGR of 10.03% between 2023 and 2028. There has been an increasing awareness regarding Alzheimer's disease across the world. In addition, there are several initiatives to increase community awareness about the condition. For instance, the funded projects provided evidence-based and evidence-informed interventions and conducted extensive education, training, and outreach programs in various US communities. Moreover, there are several other Alzheimer's programs and public initiatives, such as the National Alzheimers Plan, AFA Teens, The Alzheimers Association Walk to End Alzheimers, and The Hampden Good Neighbor Program in the US. Hence, such factors are positively impacting the market.
To learn more about this report, Request Free Sample
The hospital pharmacy segment is estimated to witness significant growth during the forecast period. This segment is considered as the major distribution channel for Alzheimer's disease therapeutics owing to the large-scale requirements of such drugs for the treatment of patients. In addition, the increasing investment by the governments of several countries, such as India and China, to improve healthcare infrastructure will fuel the growth of this segment.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was the largest segment and was valued at USD 3.55 billion in 2018. Moreover, the rapid growth in the number of hospitals in developing countries such as India and the rise in government initiatives to develop healthcare infrastructure has increased the demand. Therefore, the demand for pharmaceuticals in hospitals is also increasing. In addition, the increasing number of cases of disease will likely increase the adoption of therapeutics in hospitals worldwide. Hence, such factors are expected to propel the hospital segment, which is expected to fuel the growth of the hospital pharmacy segment of the market during the forecast period.
Advancements in medical technology, including emerging fields like Neurophotonics, which explores optical methods to study neurological conditions, are also contributing to the expansion of hospital capabilities. These innovations enhance diagnostic precision and therapeutic efficacy, thereby bolstering the role of hospital pharmacies in delivering cutting-edge treatments.
The cholinesterase segment is an important therapeutic target for Alzheimer's disease. In addition, the deterioration of cholinergic neurons in the brain and the loss of neurotransmission are the major causes of the decline in cognitive functions in patients with disease. Moreover, the main cause of disease is also a reduction in acetylcholine synthesis. Hence, one of the possible therapeutic strategies is to increase the cholinergic levels in the brain by inhibiting the biological activity of acetylcholinesterase. Furthermore, as cholinesterase inhibitors increase the availability of acetylcholine in central synapses, it has now become the main approach to the symptomatic treatment of disease. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
One of the only approved N-methyl-D-aspartate receptor antagonists for the symptomatic treatment of moderate-to-severe Alzheimer's disease is Memantine. In addition, it possesses a three-ring structure with a bridgehead amine. Under physiological conditions, it carries a positive charge that binds at the Mg2+ site within the N-methyl-D-aspartate receptor-associated channel. Moreover, according to clinical trial results, memantine can achieve its pharmacological actions and does not show the adverse effects typically associated with high-affinity NMDA blockers. Furthermore, memantine has exhibited efficacy and safety in placebo-controlled trials in patients with moderate-to-severe Alzheimer's disease. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds the major share, primarily due to the increasing awareness of the disease and its strong prevalence of Alzheimer's disease. In addition, the prevalence of the disease has been increasing at a significant rate in the developed countries of the region. Research in primary biliary cholangitis therapeutics is contributing valuable insights to the development of Alzheimer's Disease therapeutics, as both conditions involve complex immune system interactions and potential targets for innovative treatments. Moreover, the prevalence of Alzheimer's disease and other dementias is also high in Canada. For instance, In 2011, 2.23% of the total population of Canada was affected by Alzheimer's disease and other dementias. In addition, this percentage is expected to increase to 3.45% by 2031. Hence, such factors are driving the market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AB Science SA: The company offers Alzheimer disease therapeutics such as Masitinib.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is witnessing notable advancements in the field of biological therapies and amyloid beta inhibitors aimed at addressing neurodegenerative diseases. Alzheimer's disease, affecting both women and men, poses significant challenges, impacting life expectancy and cognitive function. As the prevalence of Alzheimer's and related dementias rises, there's an increasing demand for innovative therapies. Clinics and hospitals play a crucial role in providing diagnosis and treatment, often utilizing cognitive assessment systems to evaluate patients. With a growing population of Medicare beneficiaries affected by Alzheimer's, the need for effective therapeutics is pressing. These therapies target various symptoms such as memory impairment, impaired thinking, and behavioral changes, aiming to improve brain cell function and everyday tasks. Heightened awareness and consciousness of Alzheimer's disease drive research and development efforts in the quest for effective treatments.
The market is experiencing significant growth, driven by the availability and ongoing research and development of novel biomarkers. Alzheimer's disease, a neurodegenerative disorder characterized by the formation of B-amyloid plaques and neurofibrillary masses in the brain parenchyma, results in progressive memory loss.
Furthermore, the prevalence of Alzheimer's disease has surged globally, underscoring the urgent need for new therapies. Biomarkers, including blood tests, cerebral spinal fluid analysis, and neuroimaging scans such as PET and MRI, play a pivotal role in drug development by aiding in the identification and testing of disease-modifying therapies. As efforts intensify to identify effective treatments for Alzheimer's disease, fueled by advancements in biomarker research, the market is poised for substantial growth in the forecast period.
A key factor shaping the market growth is the increasing funding for therapeutics discovery. The rising prevalence of Alzheimer's disease has led to an increase in demand for its therapeutics, as well as garnered significant funding for the development of therapeutics. In addition, over the past years, different organizations and governments globally have been investing in therapeutics for Alzheimer's disease, which has resulted in scientific achievements that have benefited many people with Alzheimer's disease globally.
Moreover, the Federal Government of the US is the largest public funder of research and development of therapeutics for Alzheimer's disease. In addition, organizations such as The National Institute on Aging, the National Center for Advancing Translational Science, the National Institute of General Medical Sciences, and the National Institute of Mental Health grant funds for research on drug development for Alzheimer's disease. Hence, such factors are driving the market growth during the forecast period.
Issues associated with the diagnosis of Alzheimer's disease are one of the key challenges hindering market growth. It is still a clinical challenge to determine Alzheimer's disease at an early stage. In addition, the neuropathological changes in Alzheimer's disease start to accumulate in the brain 10-15 years before the first sign of clinical impairment.
Moreover, dementia due to Alzheimer's disease is the last stage of the disease. In addition, the major limitation of the current approaches is that the number of useful markers for every stage of the disease is less. Furthermore, markers for brain atrophy have been developed, but the condition is not always present at the early diagnosis of Alzheimer's disease. Hence, such factors are hindering the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Dementia and Movement Disorder Treatment Market: Dementia and Movement Disorder Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, France - Size and Forecast
Neurological Biomarkers Market: Neurological Biomarkers Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast
Neurophotonics Market: Neurophotonics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Spain, Japan - Size and Forecast
The market is witnessing significant advancements in treatment, with the development of biological therapies and drug discovery techniques targeting brain cells and central nervous system disorders. Amyloid beta inhibitors like Crenezumab and Tau antibodies are promising pipeline drugs in the fight against neurodegenerative diseases. Medications such as Aricept, Exelon, and Razadyne aim to improve cognitive function and behavioral skills in diagnosed patients. With an aging population and increasing awareness, there's a growing consciousness of the disease's impact, leading to a rise in the prescription rate. Furthermore, the availability of e-commerce platforms and online pharmacies facilitates access to medications for patients and caregivers, enhancing convenience in managing everyday tasks. Despite challenges, advancements in treatment offer hope for improving life expectancy and reducing disability and deaths among Medicare beneficiaries affected by Alzheimer's Disease.
Moreover, the market addresses the urgent need for effective treatments for this debilitating central nervous system disorder. With the prevalence of Alzheimer's disease rising, there's a growing consciousness of the disease and its impact on individuals, families, and healthcare systems. Pharmaceutical companies are investing heavily in research and development to combat memory impairment and cognitive decline associated with Alzheimer's. Cognitive assessment systems aid in diagnosis, while therapies targeting N-methyl D-aspartate antagonist receptors and Tau antibodies show promise in slowing disease progression. With the advent of online pharmacy and e-commerce platform, access to Alzheimer's therapeutics has become more convenient, benefiting both men and women affected by the disease. As research continues and social skills are prioritized, the Alzheimer's therapeutics market is poised for significant growth in the coming years.
The market is witnessing notable growth, driven by the increasing demand for innovative treatments in drug store & retail pharmacy and the expanding reach of e-commerce platforms. With the rise of e-commerce services, patients have easier access to medications through online pharmacies. The Internet serves as a crucial tool for disseminating information about Alzheimer's disease therapies, with platforms like the NCBI providing valuable research insights. Organizations like the Pan American Health Organization play a vital role in raising awareness and providing support. Additionally, advancements in smartphone technology enable convenient monitoring and management of the disease. Emerging treatments like tau antibody therapies are revolutionizing Alzheimer's treatment paradigms. With ongoing research and innovative thinking, the Alzheimer's disease therapeutics market is poised for significant expansion.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
168 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
|
Market Growth 2024-2028 |
USD 5.41 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.83 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, Canada, UK, Germany, and Japan |
|
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd. |
|
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
